StockData
SELLAS Life Sciences Group, Inc. logo

SELLAS Life Sciences Group, Inc. (SLS) stock

SLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/30
$17.95−1.20 (-6.27%)

Close on Nov 18, 2026Market cap $3.62BP/E –Yield –

SELLAS Life Sciences operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

SELLAS Life Sciences's operating income for the twelve months ending Jun 30, 2026 was -$35.22M. For fiscal 2025 it was -$28.27M. The highest annual figure on record is -$12.49M in fiscal 2011.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$28.27M–
FY2024Dec 31, 2024-$31.51M–
FY2023Dec 31, 2023-$37.87M–
FY2022Dec 31, 2022-$41.95M–
FY2021Dec 31, 2021-$25.29M–
FY2020Dec 31, 2020-$16.98M–
FY2019Dec 31, 2019-$20.04M–
FY2017Dec 31, 2017-$23.04M–
FY2016Dec 31, 2016-$15.99M–
FY2015Dec 31, 2015-$34.22M–
FY2014Dec 31, 2014-$43.90M–
FY2013Dec 31, 2013-$28.49M–
FY2012Dec 31, 2012-$21.20M–
FY2011Dec 31, 2011-$12.49M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$10.63M–
Q1 FY2026Mar 31, 2026-$9.25M–
Q4 FY2025Dec 31, 2025-$8.26M–
Q3 FY2025Sep 30, 2025-$7.08M–
Q2 FY2025Jun 30, 2025-$6.87M–
Q1 FY2025Mar 31, 2025-$6.06M–
Q4 FY2024Dec 31, 2024-$6.92M–
Q3 FY2024Sep 30, 2024-$7.33M–
Q2 FY2024Jun 30, 2024-$7.62M–
Q1 FY2024Mar 31, 2024-$9.65M–
Q4 FY2023Dec 31, 2023-$8.18M–
Q3 FY2023Sep 30, 2023-$9.36M–
Q2 FY2023Jun 30, 2023-$9.05M–
Q1 FY2023Mar 31, 2023-$11.28M–
Q4 FY2022Dec 31, 2022-$9.45M–
Q3 FY2022Sep 30, 2022-$7.15M–
Q2 FY2022Jun 30, 2022-$8.62M–
Q1 FY2022Mar 31, 2022-$16.74M–
Q4 FY2021Dec 31, 2021-$11.62M–
Q3 FY2021Sep 30, 2021-$6.98M–
Q2 FY2021Jun 30, 2021-$4.45M–
Q1 FY2021Mar 31, 2021-$2.25M–
Q4 FY2020Dec 31, 2020-$4.16M–
Q3 FY2020Sep 30, 2020-$4.49M–
Q2 FY2020Jun 30, 2020-$4.27M–
Q1 FY2020Mar 31, 2020-$4.06M–
Q4 FY2017Dec 31, 2017-$8.58M-198.1%
Q3 FY2017Sep 30, 2017-$4.46M–
Q2 FY2017Jun 30, 2017-$4.91M–
Q1 FY2017Mar 31, 2017-$5.09M–
Q4 FY2016Dec 31, 2016$8.74M–
Q3 FY2016Sep 30, 2016-$6.47M–

More SELLAS Life Sciences figures

See a number that looks wrong?